Adverse events: malignancy · kidney transplant recipients
Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in adverse events: malignancy compared with standard dose CNI (low certainty).
1 finding from 1 review
Adverse events: lymphocele · kidney transplant recipients
Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in adverse events: lymphocele compared with standard dose CNI (low certainty).
1 finding from 1 review
Death · kidney transplant recipients
Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in death compared with standard dose CNI (moderate certainty).
1 finding from 1 review
Acute rejection · kidney transplant recipients
Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in acute rejection compared with standard dose CNI (moderate certainty).
1 finding from 1 review
GFR · kidney transplant recipients
1 finding from 1 review
Graft loss · kidney transplant recipients
Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in graft loss compared with standard dose CNI (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · kidney transplant recipients
Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: hypertension compared with standard dose CNI (low certainty).
1 finding from 1 review
Adverse events: CMV infection · kidney transplant recipients
Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: CMV infection compared with standard dose CNI (low certainty).
1 finding from 1 review
Adverse events: malignancy · kidney transplant recipients
Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: malignancy compared with standard dose CNI (low certainty).
1 finding from 1 review
Acute rejection: avoidance · kidney transplant recipients
Calcineurin inhibitor (CNI) avoidance and late withdrawal with… showed no clear difference in acute rejection: avoidance compared with standard dose CNI (moderate certainty).
1 finding from 1 review
Acute rejection: late withdrawal · kidney transplant recipients
Calcineurin inhibitor (CNI) avoidance and late withdrawal with… probably leads to higher acute rejection: late withdrawal compared with standard dose CNI (moderate certainty).
1 finding from 1 review
GFR: avoidance · kidney transplant recipients
1 finding from 1 review
GFR: late withdrawal · kidney transplant recipients
1 finding from 1 review
Graft loss: avoidance · kidney transplant recipients
Calcineurin inhibitor (CNI) avoidance and late withdrawal with… showed no clear difference in graft loss: avoidance compared with standard dose CNI (moderate certainty).
1 finding from 1 review
Graft loss: late withdrawal · kidney transplant recipients
Calcineurin inhibitor (CNI) avoidance and late withdrawal with… showed no clear difference in graft loss: late withdrawal compared with standard dose CNI (moderate certainty).
1 finding from 1 review
Death at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes death at final compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review
End‐stage renal disease · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes end‐stage kidney disease at final compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review
Total remission (complete or partial) at final · primary membranous nephropathy in adults with nephrotic syndrome
Calcineurin inhibitors ± steroids showed no clear difference in total remission at final compared with placebo/no treatment/supportive treatment/steroids (low certainty).
1 finding from 1 review
Complete remission · primary membranous nephropathy in adults with nephrotic syndrome
Calcineurin inhibitors ± steroids showed no clear difference in complete remission at final compared with placebo/no treatment/supportive treatment/steroids (low certainty).
1 finding from 1 review
Relapse · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes recurrence of disease (relapse) at final compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review